

DMG Deutsche Malaria GmbH, Neuer Wall 72, 20354 Hamburg

Dr Henning Gädeke, the Chair of the Global Health EDCTP3
Joint Undertaking Governing Board
c/o Dr Michael Makanga, the Global Health EDCTP3
Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

Ihre Ref./Ihre Nachricht vom

Unsere Ref. /Unsere Nachricht vom
DH/-

Telephone
040/81 80 28

Name

Datum
02.09.2025

Letter of endorsement

Dear Sir/Madam,

On behalf of DMG Deutsche Malaria GmbH (DMG) and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

DMG is a private company dedicated to research with the aim of advancing new therapies for malaria and, in due pursuance of this mission, seeks firm and sustainable collaborations with health authorities, academic institutions and teaching hospitals in areas where this disease is endemic.

In the absence of feedback from Global Health EDCTP3 before the proposal deadline, this document serves as a provisional letter of endorsement:

DMG commits to contribute in-kind (IKOP) support through the provision of both oral and intravenous formulations of fosmidomycin which are critical to the implementation of the project.

The total value of this contribution is estimated to be EUR 390,000 for the 60-month duration of the project as in-kind contribution:

- Consulting expenses EUR 210,000
- Salaries EUR 150,000
- Overheads EUR 30,000

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model

Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.

2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

Dr David Hutchinson
Managing Director



DMG Deutsche Malaria GmbH